{
    "clinical_study": {
        "@rank": "117700", 
        "arm_group": [
            {
                "arm_group_label": "Risedronate and calcium and vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "35 mg Risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IE vitamin D3 daily for 12 months. Group B (bisphosphonate group)"
            }, 
            {
                "arm_group_label": "Nutritional supplement, Risedronate, calcium and vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)"
            }, 
            {
                "arm_group_label": "Calcium and vitamin D3", 
                "arm_group_type": "Other", 
                "description": "An oral dose of 1000 mg Calcium and 800 IE vitamin D3 daily for 12 months.        Group C (control)"
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis is that nutritional supplementation together with bisphosphonates have\n      a preserving effect on bone mineral density (BMD) and lean body mass in elderly hip fracture\n      patients."
        }, 
        "brief_title": "Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture", 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": "Hip Fracture", 
        "condition_browse": {
            "mesh_term": [
                "Fractures, Bone", 
                "Hip Fractures"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion criteria: Men and women, \u2265 60 years of age with a recent fracture of the femoral\n      neck or trochanter, admitted to any of the four University hospitals in Stockholm, Sweden.\n                                                              Patients are randomized into three\n      groups by sealed enveloped technique in blocks by 12, thus assuring that each center had an\n      equal distribution of patients in the three treatment groups. Patients randomly assigned and\n      followed for 12 months. Each center with a doctor in charge and a trial nurse. The trial\n      nurse in collaboration with the doctor are responsible of the randomization procedure and\n      that blood samples are taken in the morning of the first weekday after inclusion at the ward\n      and further that the dual-energy X-ray (DXA) and all estimates are done during hospital\n      stay.The pharmacological treatment and nutritional supplementation starts as soon as the\n      patients are circulatory stable, able to take food by mouth and are able to sit in an\n      upright position one hour after taking the tablets.Patients are examined at baseline with a\n      follow up at 6 and 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 60 years\n\n          -  Recent fracture of the femoral neck or trochanter\n\n          -  Without severe cognitive impairment\n\n          -  Ambulant before fracture\n\n          -  BMI \u2264 28\n\n        Exclusion Criteria:\n\n          -  Abnormal parameters regarding liver i.e. S-Alanine aminotransferase (S-ALAT) and\n             S-Aspartate aminotransferase (S-ASAT) \u2265 twice as normal\n\n          -  Abnormal parameters regarding kidney i.e. S-Creatinine > 130 \u00b5g/L\n\n          -  Primary hyperparathyroidism, osteogenesis imperfecta, Paget\u00b4s disease\n\n          -  Myeloma\n\n          -  Lactose intolerance\n\n          -  Dysphagia\n\n          -  Esophagitis\n\n          -  Gastric ulcer\n\n          -  Malignancy\n\n          -  Diabetes with nephropathy or retinopathy\n\n          -  Active iritis or uveitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "79", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950169", 
            "org_study_id": "NutristudienSHFG"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Risedronate and calcium and vitamin D3", 
                    "Nutritional supplement, Risedronate, calcium and vitamin D3"
                ], 
                "intervention_name": "Risedronate", 
                "intervention_type": "Drug", 
                "other_name": "Bisphosphonate Group (B)"
            }, 
            {
                "arm_group_label": "Nutritional supplement, Risedronate, calcium and vitamin D3", 
                "intervention_name": "Nutritional supplement", 
                "intervention_type": "Other", 
                "other_name": "Bisphosphonate and nutritional supplemented Group (BN)"
            }, 
            {
                "arm_group_label": [
                    "Risedronate and calcium and vitamin D3", 
                    "Nutritional supplement, Risedronate, calcium and vitamin D3", 
                    "Calcium and vitamin D3"
                ], 
                "intervention_name": "Calcium and vitamin D3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Control Group (C)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Risedronic acid", 
                "Calcium, Dietary", 
                "Cholecalciferol", 
                "Diphosphonates", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hip fracture", 
            "Nutritional supplement", 
            "Bisphosphonates", 
            "Bone mineral density", 
            "Body composition"
        ], 
        "lastchanged_date": "October 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stockholm", 
                    "country": "Sweden", 
                    "zip": "SE-141 86"
                }, 
                "name": "Department of Geriatric Medicine R94, Karolinska University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture", 
        "overall_official": [
            {
                "affiliation": "Karolinska Institutet", 
                "last_name": "Margareta Hedstr\u00f6m, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Karolinska Institutet", 
                "last_name": "Maria S\u00e4\u00e4f, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Karolinska Institutet", 
                "last_name": "Lena Flodin, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Sweden: Regional Ethical Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Total hip bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) at baseline and at 6 and 12 months follow up.", 
            "measure": "Total hip bone mineral density (BMD) at 6 and 12 months after hip fracture.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950169"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Karolinska Institutet", 
            "investigator_full_name": "Lena Flodin", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Total body composition measured by dual X-ray absorptiometry (DXA) at baseline and at 6 and 12 months follow up.", 
            "measure": "Total body bone mineral density (BMD), lean and fat mass at 6 and 12 months after hip fracture.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Karolinska Institutet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karolinska Institutet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2004", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}